Supply of Polibar Acb Disposable Barium Enema Kit by Bracco Pty Ltd

Overview

The Therapeutic Goods Act 1989 (the Act), enacted by the Australian Parliament, is designed to regulate therapeutic goods in Australia, ensuring they are safe, of high quality, and effective. The Act aims to protect public health by controlling the importation, supply, and advertising of therapeutic goods. One specific problem the Act was introduced to address is the regulation of the quality and safety of therapeutic goods, ensuring that products meet specified standards before they are made available to the public. Section 14 and 14A of the Act provide a mechanism for the Secretary to the Department of Health to consent to the supply of goods that do not fully comply with certain standards, provided specific conditions are met to ensure the safety and efficacy of the product. This legislative provision allows for flexibility in certain circumstances while maintaining a high standard of public health protection.

Scope and Application

The Therapeutic Goods Act 1989 applies to a broad range of therapeutic goods, including medicines, medical devices, and blood products, that are manufactured, supplied, or advertised within Australia. This Act regulates the therapeutic goods industry to ensure that products available to the public are safe, of high quality, and perform as represented. The Act applies to persons and entities involved in the manufacture, supply, and advertising of therapeutic goods, and it extends its reach across all states and territories of Australia. Certain goods, such as therapeutic goods used for personal, non-commercial use, may be subject to exemptions or exclusions from the Act's requirements. Additionally, the Act allows for the creation of subordinate instruments to further define and regulate specific aspects of the therapeutic goods industry, thereby extending or restricting the application of the primary Act. In this particular instance, the legislation authorises Mayada Kayali, as a delegate of the Secretary to the Department of Health and Ageing, to provide consent for Bracco Pty Ltd to supply a specific product, POLIBAR ACB DISPOSABLE BARIUM ENEMA KIT, under certain conditions. This consent is granted despite the product not meeting the shelf-life limit for loss on drying as specified by the British Pharmacopoeia and the United States Pharmacopoeia, provided that the product complies with other aspects of the standard and meets specific loss on drying limits at release and at the end of its shelf-life. This decision demonstrates the flexibility within the Therapeutic Goods Act to allow for the supply of therapeutic goods under controlled conditions where necessary, ensuring that public health is protected while accommodating practical considerations in the industry.

Key Provisions

Section 14 and 14A of the Therapeutic Goods Act 1989 (the Act) provide a mechanism for the delegate of the Secretary to the Department of Health and Ageing to consent to the supply of therapeutic goods that do not fully meet the specified standards. In this case, the delegate, Mayada Kaylali, has granted permission for Bracco Pty Ltd to supply POLIBAR ACB DISPOSABLE BARIUM ENEMA KIT, a product that does not comply with the shelf-life limit for loss on drying of no more than 1% as specified by the British Pharmacopoeia and the United States Pharmacopoeia. This consent, however, is subject to certain conditions stipulated under section 15(1) of the Act. The conditions for this consent are quite specific. Firstly, the product must comply with all other aspects of the standard, ensuring that it meets all other necessary requirements except for the shelf-life limit for loss on drying. Secondly, the product must comply with the limit of not more than 1% loss on drying at the point of release. This means that when the product is first manufactured and supplied, it must adhere to this loss on drying limit. Lastly, the product must also comply with the limit of not more than 1.5% loss on drying at the end of its shelf-life. This condition ensures that even as the product ages, it does not exceed the specified limit. Under the Act, both Bracco Pty Ltd and the delegate of the Secretary have distinct obligations. Bracco Pty Ltd is required to ensure that the product supplied meets the specified conditions regarding the loss on drying limit at release and at the end of the shelf-life. This involves rigorous testing and quality control processes to verify compliance. On the other hand, Mayada Kaylali, as the delegate of the Secretary, must ensure that the conditions attached to the consent are adhered to, thereby maintaining the standards and safety of therapeutic goods supplied in Australia. Failure to comply with the conditions stipulated in the consent may result in various legal consequences. Under the Act, breaches of the terms of consent can be considered offences. The specific penalties for such breaches are not detailed in the provided text, but generally, penalties for non-compliance with the Therapeutic Goods Act can include fines and, in severe cases, imprisonment. The exact penalties can vary depending on the nature and severity of the breach, and they are determined by the courts. Additionally, repeated or significant breaches may lead to further regulatory actions, including the revocation of authorisation or supply permits.